

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5596629

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT		
NATURE OF CONVEYANCE:	Corrective Assignment to correct the APPLICATION NUMBER 29576454 previously recorded on Reel 049540 Frame 0808. Assignor(s) hereby confirms the ASSIGNMENT.		
CONVEYING PARTY DATA			
Name			Execution Date
MICELLE BIOPHARMA, INC.			08/08/2018
RECEIVING PARTY DATA			
Name:	PINNACLE BANK		
Street Address:	150 3RD AVENUE SOUTH, 8TH FLOOR		
City:	NASHVILLE		
State/Country:	TENNESSEE		
Postal Code:	37201		
PROPERTY NUMBERS Total: 1			
Property Type	Number		
Application Number:	29575454		
CORRESPONDENCE DATA			
Fax Number:	(919)653-0435		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	919.573.7439		
Email:	USPATENT@NEXSENPRUET.COM		
Correspondent Name:	E. ERIC MILLS		
Address Line 1:	4141 PARKLAKE AVENUE		
Address Line 2:	SUITE 200		
Address Line 4:	RALEIGH, NORTH CAROLINA 27612		
ATTORNEY DOCKET NUMBER:	060971-00005		
NAME OF SUBMITTER:	E. ERIC MILLS		
SIGNATURE:	/E. Eric Mills/		
DATE SIGNED:	06/28/2019		
Total Attachments: 26			
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page1.tif			
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page2.tif			
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page3.tif			
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page4.tif			

source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page5.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page6.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page7.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page8.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page9.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page10.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page11.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page12.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page13.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page14.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page15.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page16.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page17.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page18.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page19.tif
source=Notice of Recordation#page1.tif
source=Notice of Recordation#page2.tif
source=Notice of Recordation#page3.tif
source=Notice of Recordation#page4.tif
source=Confirmation of Original Assignment#page1.tif
source=Confirmation of Original Assignment#page2.tif
source=Confirmation of Original Assignment#page3.tif

Exhibit B
Notice Filing

INTELLECTUAL PROPERTY SECURITY AGREEMENT

THIS INTELLECTUAL PROPERTY SECURITY AGREEMENT (this "Agreement") is made and entered into as of August 8, 2018, by and between PINNACLE BANK ("Lender"), and MICELLE BIOPHARMA, INC., a Delaware corporation ("Pledgor").

WITNESSETH:

WHEREAS, contemporaneously herewith, Lender is providing financing (the "Loan") to Pledgor pursuant to that certain Loan and Security Agreement of even date herewith by and between Pledgor and Lender (as may be amended or restated from time to time, the "Loan Agreement"; capitalized terms not otherwise defined herein and not otherwise noted as being defined elsewhere shall have the meanings set forth in the Loan Agreement) and the other Loan Documents (as defined in the Loan Agreement);

WHEREAS, pursuant to the Loan Agreement, Pledgor is granting to Lender a security interest and lien in and to all of Pledgor's now owned or hereafter acquired assets, including, without limitation, all patents, trademarks, trademark registrations, trade names, copyrights, all applications therefor and all other intellectual or proprietary rights or interests of any kind, nature or description whatsoever for the purpose of securing the Loan and other Obligations (as defined in the Loan Agreement); and

WHEREAS, Lender is willing to provide the Loan to Pledgor on the condition that Pledgor executes and delivers this Agreement to Lender; and

NOW, THEREFORE, in consideration of and as a condition to the Loan, the mutual promises and understandings of Pledgor and Lender set forth herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Pledgor covenants unto and agrees with Lender as follows:

1. **Collateral Assignment of Intellectual Property.** To secure the full and timely payment and performance of the Loan and the Obligations, Pledgor hereby grants and conveys to Lender a security interest and lien in and to, and collaterally assigns to Lender, all of Pledgor's right, title and interest in and to all of its now owned or existing and hereafter acquired or arising (collectively the "Intellectual Property Collateral");

A. (i) trademarks, trademark registrations and applications therefor, including, without limitation, the trademarks, trademark registrations and applications listed on Exhibit A, (ii) renewals thereof, (iii) all income, royalties, damages and payments now and hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past or future infringements thereof, (iv) the right to sue for past, present and future infringements thereof, and (v) all rights corresponding thereto throughout the world (collectively the "Trademarks");

B. (i) patents, patent registrations and applications therefor, including, without limitation, the inventions and improvements claimed in connection therewith, and the patents, patent registrations and the applications listed on Exhibit A, (ii) renewals, reissues, divisions, continuations, extensions and continuations-in-part thereof, (iii) all income, royalties, damages and payments now or hereafter due or payable under or with respect thereto, including, without limitation, damages and payments for past or future infringements thereof, (iv) the right to sue for past, present and future infringements thereof; and (v) all rights corresponding thereto throughout the world (collectively the "Patents");

C. (i) copyrights and applications for registration, including, without limitation, the copyrights and applications for registration listed on Exhibit A, (ii) renewals thereof, (iii) all income, royalties, damages and payments now and hereafter due or payable under or with respect thereto, including, without limitation, damages and payments for past or future infringements thereof, (iv) the right to sue for past, present and future infringements thereof, and (v) all rights corresponding thereto throughout the world (collectively the "Copyrights");

D. license agreements for Trademarks, Patents and Copyrights, whether Pledgor is a licensor or licensee under any such license agreement, including, without limitation, the licenses listed on Exhibit A (collectively the "Licenses"); and

E. the goodwill of Pledgor's business connected with and symbolized by the Trademarks, Patents, Copyrights and Licenses;

provided, however, that the Intellectual Property Collateral shall not include (i) "intent-to-use" trademark applications, in each case until such time as Pledgor files a verified statement of use with respect to such trademark applications and (ii) license agreements for Trademarks, Patents and Copyrights, where Pledgor is a licensee under any such license agreement and such license agreement prohibits the pledge of Pledgor's rights under the license agreement.

Pledgor covenants and agrees to execute and deliver to Lender all agreements, instruments, documents and other written matter that Lender may reasonably request, in form and substance reasonably acceptable to Lender, to perfect and maintain perfected Lender's security interests and lien in and to the Intellectual Property Collateral.

2. **Recordation.** The Pledgor authorizes and request that the Register of Copyrights, the Commissioner of Patents and Trademarks and any other applicable government officer record this Intellectual Property Security Agreement.


3. **Governing Law.** This Agreement shall be governed by the laws of the State of Tennessee. Any term used in this Agreement that is defined in the Uniform Commercial Code as in effect in the State of Delaware on the date of this Agreement and that is not otherwise defined in this Agreement or in the Loan Agreement shall have the meaning given to that term therein.

[Signature page follows]

IN WITNESS WHEREOF, Pledgor's duly authorized officer has executed this Agreement as of the date first set forth above.

PLEDGOR:

MICELLE BIOPHARMA, INC.,
a Delaware corporation

By: 
Name: JOHN MAYO
Title: PRESIDENT

25185548.2

EXHIBIT A

Trademarks, Patents, Copyrights, Licenses

Trademarks:

See the Heading labeled “Trademark Holdings” on Attachment 5.19, which is incorporated herein in its entirety.

Patents:

See the Heading labeled “Patent Holdings” on Attachment 5.19, which is incorporated herein in its entirety.

Copyrights

None.

IP Agreements

1. Master Services Agreement, dated January 30, 2015, as amended, between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc.
2. Exclusive Development and License Agreement, dated January 7, 2010, by and between SPC and Mylan Pharmaceuticals Inc., as amended by the Amendment to Exclusive Development and License Agreement, dated April 12, 2013, by and between Sancilio Pharmaceuticals Company, Inc. and Mylan Pharmaceuticals Inc.
3. Master Services Agreement, dated September 30, 2010, by and between Sancilio Pharmaceuticals Company, Inc. and Mylan Pharmaceuticals Inc.
4. Development Agreement, dated April 26, 2012, by and between Sancilio Pharmaceuticals Company, Inc. and PACK Pharmaceuticals, LLC, as amended on November 10, 2017.
5. Statement of Work #01, dated December 21, 2017, between Sancilio Pharmaceuticals Company, Inc. and PHF SA.
6. Master Services Agreement, dated April 17, 2012, by and between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc., as supplemented by various Statements of Work, Change Orders and/or Letters of Authorization.
7. Consulting Agreement dated April 30, 2013, by and between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc.

SCHEDULE 5.19

Intellectual Property

Trademarks:

See the Heading labeled "Trademark Holdings" on Attachment 5.19, which is incorporated herein in its entirety.

Patents:

See the Heading labeled "Patent Holdings" on Attachment 5.19, which is incorporated herein in its entirety.

Copyrights

None.

IP Agreements

1. Master Services Agreement, dated January 30, 2015, as amended, between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc.
2. Exclusive Development and License Agreement, dated January 7, 2010, by and between SPC and Mylan Pharmaceuticals Inc., as amended by the Amendment to Exclusive Development and License Agreement, dated April 12, 2013, by and between Sancilio Pharmaceuticals Company, Inc. and Mylan Pharmaceuticals Inc.
3. Master Services Agreement, dated September 30, 2010, by and between Sancilio Pharmaceuticals Company, Inc. and Mylan Pharmaceuticals Inc.
4. Development Agreement, dated April 26, 2012, by and between Sancilio Pharmaceuticals Company, Inc. and PACK Pharmaceuticals, LLC, as amended on November 10, 2017.
5. Statement of Work #01, dated December 21, 2017, between Sancilio Pharmaceuticals Company, Inc. and PHF SA.
6. Master Services Agreement, dated April 17, 2012, by and between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc., as supplemented by various Statements of Work, Change Orders and/or Letters of Authorization.
7. Consulting Agreement dated April 30, 2013, by and between Sancilio Pharmaceuticals Company, Inc. and TherapeuticsMD, Inc.
8. Exclusive Supply Agreement, dated July 7, 2017, by and between Sancilio Pharmaceuticals Company, Inc. and KD Pharma GmbH, as amended by Amendment No. 1 dated January 8, 2018 .

9. Master Services Agreement, dated January 1, 2018, by and between Sancilio Pharmaceuticals Company, Inc. and AmerisourceBergen Drug Corporation, as supplemented by the PRxO Generics Program Addendum of January 1, 2018.
10. Group Purchasing Agreement, dated August 21, 2016, between Sancilio Pharmaceuticals Company, Inc. and Rx Sourcing Strategies, LLC, as amended.
11. Distribution Agreement dated February 28, 2017, between Sancilio Pharmaceuticals Company, Inc. and BMG Pharma S.r. l.
12. Statement of Work, dated January 8, 2014, between Sancilio Pharmaceuticals Company, Inc. and Bongo Pharmaceutical, Inc.
13. Consulting Agreement, dated June 24, 2013, by and between Dr. Frederick D. Sancilio and TherapeuticsMD, Inc.

Trademark Holdings

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
PREPARE	United States (US)	Sancilio & Company, Inc.	N/A	85833997	1/24/2013		
IDENT	United States (US)	Sancilio & Company, Inc.	N/A	77865700	11/5/2009	3869394	IC 005 Chewable fluoride tablet for the prevention of dental caries
AVC	United States (US)	Sancilio & Company, Inc.	N/A	77778745	7/19/2009	3601019	Class 5: Chewable multivitamin tablets
CEBOLITZ	United States (US)	Sancilio & Company, LLC (original, but then assigned to other party)	N/A	77067114	12/19/2006	3412283	Class 3: Breath freshener Class 30: Candy, candy mints
MYRISTAMATE	United States (US)	Sancilio & Company, Inc.	N/A	77262975	6/23/2007	3554899	Class 1: Naturally occurring combination of myristic acid and myristoleic acid used as an ingredient in the manufacture of dietary and nutritional supplements Class 5: Naturally occurring combination of myristic acid and myristoleic acid for use as a component of dietary and nutritional supplements and as a dietary and nutritional supplement

PATENT

Trademark Holdings

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and F.A. Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
DEVELOPING GOOD SCIENCE INTO GREAT MEDICINE	United States (US)	Sandoz & Company, Inc.	N/A	86708016	7/29/2015	4878377	IC 005: Dietary and nutritional supplements; Dietary supplements for human consumption; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Multi-vitamin preparations; Vitamin supplements
ADVANCED LIPID TECHNOLOGIES	United States (US)	Sandoz & Company, Inc.	N/A	86628798	5/13/2015	5215442	IC 005: Drug delivery agents, consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for delivery of lipid based pharmaceutical preparations.


PATENT

Trademark Holdings

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and F/A Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
SANCILLO PHARMACEUTICALS COMPANY, INC.	US	Sancillo Pharmaceuticals Company, Inc.	N/A	88735258	8/24/2015	5314532	Class 5: Drug delivery systems consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agent in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceutical preparations for the prevention of various human disorders, namely sickle cell disease, short bowel syndrome, hypertyglyceridemia, and inflammatory disorders; pharmaceutical preparations for the treatment and prevention of various human disorders, namely sickle cell disease, short bowel syndrome, hypertyglyceridemia, and inflammatory disorders; pharmaceutical preparations for the treatment of various human disorders, namely sickle cell disease, short bowel syndrome, hypertyglyceridemia, and inflammatory disorders.
	United States (US)	Sancillo & Company, Inc.	N/A	88694358	7/19/2015	4892611	IC 005: Dietary and nutritional supplements. Dietary supplements for human consumption. Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals. Multi-vitamin preparations. Vitamin supplements.

Trademark Holdings

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and F.A. Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
ALT	United States (US)	Sancilio & Company, Inc.	N/A	85628785	5/13/2015	5032780	IC 005: Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals, pharmaceutical preparations for delivery of lipid-based pharmaceutical preparations
ETHYL CERVOONATE	United States (US)	Sancilio & Company, Inc.	N/A	87110717	7/20/2016		IC 005: Pharmaceutical preparations for the treatment and prevention of sickle cell disease, short bowel syndrome, hypertrophic cardiomyopathy, and inflammatory disorders
ABSORVIA	United States (US)	Sancilio & Company, Inc.	N/A	87139990	8/16/2016		IC 005: prenatal vitamins, nutraceuticals for use as a dietary supplement
DIALACTIVE	United States (US)	Sancilio & Company, Inc.	N/A	87181487	9/23/2016		IC 005: Dietary supplements; Dietary supplements consisting primarily of calcium and omega-3
ADVANCED LIPID TECHNOLOGIES	United States (US)	Sancilio & Company, Inc.	N/A	87101330	7/12/2016	5166729	IC 040: Contract manufacturing in the field of drug delivery agents; IC 042: Pharmaceutical research and development; Scientific research and development
OLEALIFE	United States (US)	Sancilio & Company, Inc.	N/A	87234112	11/11/2016		IC 005: Dietary supplements
ALL-IN-ONE	United States (US)	Sancilio & Company, Inc.	N/A	87503170	6/23/2017		IC 005: Nutritional supplements; Dietary and nutritional supplements containing calcium, omega-3 and D3

PATENT

REEL: 049629 FRAME: 0154

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
SANCILLO PHARMACEUTICALS	China (CN)	Sancillo Pharmaceuticals Company, Inc.	S&F	25543609	7/27/2017		IC 005: Dietary and nutritional supplements; Dietary supplements for human consumption; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Multi-vitamin preparations; Vitamin supplements.
ALTEMA	United States (US)	Sancillo & Company, Inc.	N/A	87/523,640	7/11/2017		IC 005: Pharmaceutical preparations for treatment of lipid imbalances, including sickle cell disease
AYLIK3	United States (US)	Sancillo & Company, Inc.	N/A	87/523,661	7/11/2017	6432269	IC 005: Dietary and nutritional supplements containing omega-3 vitamin D, and calcium; Dietary and nutritional supplements
ALT	Europe (EU)	Sancillo & Company, Inc.					
ADVANCED LIPID TECHNOLOGIES	Europe (EU)	Sancillo & Company, Inc.					

PATENT

REEL: 049629 FRAME: 0155

Attachment 5.19 – “Patent Holdings”

Patent Holdings

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.PR	Omega-3 Compositions and Methods for Enhanced Systemic Absorption (SC401B.PR)	United States (US)		61/618,161
SC401B.PCT	Omega-3 Fatty Acid Ester Compositions (SC401B.PCT)	International (PCT)		US2013/030211
	Pharmaceutical Compositions (EO Provisional)	United States (US)		61/775,865
	Pharmaceutical Composition For The Controlled Release Of Calcium	United States (US)		
	Pharmaceutical Composition With Reduced Food Effect	United States (US)		
	Soft Gelatin Capsule Drying Process	United States (US)		
	Formulations for Solubilizing Hormones	United States (US)		61/871,415
	Drug Delivery Systems Containing Monocyclones	United States (US)		61/848,924
SC440.PR	Formulations for Solubilizing Hormones (SC440.PR)	United States (US)		62/025,717
SC401B.US1	Omega-3 Fatty Acid Ester Compositions (SC401B.US1)	United States (US)		14/458,731
SC401B.US2	Omega-3 Fatty Acid Ester Compositions (SC401B.US2)	United States (US)		14/458,750
SC401B.DZ	Omega-3 Fatty Acid Ester Compositions (SC401B.DZ)	Algeria (DZ)		140557

PATENT

REEL: 049629 FRAME: 0156

Patent Holdings

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.AU	Omega-3 Fatty Acid Ester Compositions ("SC401B.AU")	Australia (AU)	Sprison (PI24697)	2013210427
SC401B.BR	Omega-3 Fatty Acid Ester Compositions ("SC401B.BR")	Brazil (BR)		BR1120140242313
SC401B.CA	Omega-3 Fatty Acid Ester Compositions ("SC401B.CA")	Canada (CA)		2,867,168
SC401B.CN	Omega-3 Fatty Acid Ester Compositions ("SC401B.CN")	China (CN)		201380027275.8
SC401B.CO	Omega-3 Fatty Acid Ester Compositions ("SC401B.CO")	Colombia (CO)		14-240867
SC401B.EG	Omega-3 Fatty Acid Ester Compositions ("SC401B.EG")	Egypt (EG)		1471/2014
SC401B.EP	Omega-3 Fatty Acid Ester Compositions ("SC401B.EP")	Europe (EP)		13712624.9
SC401B.IN	Omega-3 Fatty Acid Ester Compositions ("SC401B.IN")	India (IN)		8449/DELNP/2014
SC401B.IL	Omega-3 Fatty Acid Ester Compositions ("SC401B.IL")	Israel (IL)	Reinhold Cohn & Partners (2309898-YF)	234814
SC401B.JP	Omega-3 Fatty Acid Ester Compositions ("SC401B.JP")	Japan (JP)		2015-503245
SC401B.MY	Omega-3 Fatty Acid Ester Compositions ("SC401B.MY")	Malaysia (MY)		PI 2014002668
SC401B.MX	Omega-3 Fatty Acid Ester Compositions ("SC401B.MX")	Mexico (MX)		MX/a/2014/011596
SC401B.RU	Omega-3 Fatty Acid Ester Compositions ("SC401B.RU")	Russia (RU)		2014141408

Patent Holdings

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.KR	Omega-3 Fatty Acid Ester Compositions ("SC401B.KR")	South Korea (KR)		2014-7029132
SC401B.AE	Omega-3 Fatty Acid Ester Compositions ("SC401B.AE")	United Arab Emirates (AE)		P1050/14
SC403.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Fetal Malabsorption Syndromes ("SC403.PR")	United States (US)		62/062,638
SC404.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Primary Sclerosing Cholangitis ("SC404.PR")	United States (US)		62/062,643
SC410.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Non- Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis ("SC410.PR")	United States (US)		62/062,646
SC430.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Neurodegenerative Diseases ("SC430.PR")	United States (US)		62/062,651
SC411.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Sickle Cell Disease ("SC411.PR")	United States (US)		62/062,652

Patent Holdings

Green = Issued
 Red = Abandoned/Expired
 White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC412.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Macular Degeneration ("SC412.PR")	United States (US)		62/062,634
SC401B.CIP.1A	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1A")	United States (US)		14/578,709
SC401B.CIP.1B	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1B")	United States (US)		14/578,692
SC401B.CIP.1C	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1C")	United States (US)		14/578,697
SC402.CIP.1	Omega-3 Fatty Acid Ester Compositions ("SC402.CIP.1")	United States (US)		15/058,228
SC401B.HK	Omega-3 Fatty Acid Ester Compositions ("SC401B.HK")	Hong Kong (HK)		15/05834.2
SC401B.US3	STABLE MICELLES OF FATTY ACID ESTERS ("SC401B.US3")	United States (US)		14/808,835
SC401B.US4	STABLE MICELLES OF MIXED FATTY ACIDS ("SC401B.US4")	United States (US)		14/808,777
SC401B.US5	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE ("SC401B.US5")	United States (US)		14/808,809
SC401B.US6	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASES ("SC401B.US6")	United States (US)		14/808,847

Patent Holdings

Green = Issued
 Red = Abandoned/Expired
 White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B US7	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF MACULAR DEGENERATION AND PRIMARY SCLEROSING CHOLANGITIS (SC401B US7)	United States (US)		14/808 886
SC401B US8	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF DISEASE STATES (SC401B US8)	United States (US)		14/808 871
SC401B US9	FUNCTIONAL FOODS AND KITS CONTAINING STABLE MICELLES OF FATTY ACID ESTERS (SC401B US9)	United States (US)		14/808 876
SC400 PR	ENHANCED TREATMENT OF DISEASE STATES UTILIZING ADVANCED LIPID TECHNOLOGIES	United States (US)		62/207 072
SC400E	SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES (SC400E)	International (PCT)		PCT/US2015/054933
SC401B CIP 1A CIP	Omega-3 Fatty Acid Ester Compositions (SC401B CIP 1A CIP)	United States (US)		15/132 278
SC401B CIP 1B CIP	Omega-3 Fatty Acid Ester Compositions (SC401B CIP 1B CIP)	United States (US)		15/134 419
SC401B CIP 1C CIP	Omega-3 Fatty Acid Ester Compositions (SC401B CIP 1C CIP)	United States (US)		15/134 417

Patent Holdings

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.EP.DIV	Omega-3 Fatty Acid Ester Compositions ("SC401B.EP.DIV")	Europe (EP)		16165946.1
SC400E.US	SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES ("SC400E.US")	United States (US)		15/130.430
SC_DES	Method for a Medical Dosage Form	United States (US)	N/A	39/575,454
SC401B.IL.DIV	Omega-3 Fatty Acid Ester Compositions ("SC401B.IL.DIV")	Israel (IL)	Reinhold Cohn & Partners (2462403-YF)	249821
SC400E.ZA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E.ZA")	South Africa (ZA)	Spoor & Fisher (PA167379/Z4)	2017/023385
SC400E.CA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E.CA")	Canada (CA)	Osler (PCA29385)	2,963,962
SC400E.CL	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E.CL")	Chile (CL)	Balder JP Law (P170836CL)	2017-00867
SC400E.EP	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E.EP")	Europe (EP)	HGF Limited (P241710EP/KL.TJ/G)	15/7848771

Patent Holdings

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC400E.MX	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.MX)	Mexico (MX)	Vadillo & King (6566)	MX/A/2017/004324
SC400E.NG	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.NG)	Nigeria (NG)	Spoor & Fisher (PA512667/NG/MLG)	Not yet issued
SC400E.OM	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.OM)	Oman (OM)	Saba & Company (OM/T43782/998/17)	OM/P/2017/00101
SC400E.AP	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.AP)	ARIPO (AP)	Spoor & Fisher (PA512667/AP/MLG)	FI/P/2017/200
SC400E.BR	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.BR)	Brazil (BR)	Daniel Legal & IP Strategy (173.759-7)	BR1120170674281
SC400E.IN	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.IN)	India (IN)	Kan & Krishne (KC20170311062)	2.01717E+11
SC400E.SA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.SA)	Saudi Arabia (SA)	Saba & Company (SA/T43782/809/17)	517381254

Patent Holdings

Green = Issued
Red = Abandoned/Expired
White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.CIP, 1C.CIP, CON	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP, CON")	United States (US)	N/A	15/590,420
SC400E_US, CON	Self-Mitcellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E_US, CON")	United States (US)	N/A	15/605972
SC411, PR2	Sickle Cell Disease Treatment Utilizing Omega-3 Fatty Acids	United States (US)	N/A	62/563433

APPLICATION NUMBER: 15180430 FILING DATE: 06/13/2016
PATENT NUMBER: ISSUE DATE:
TITLE: SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS
AND THEIR USE IN THE TREATMENT OF DISEASE STATES

APPLICATION NUMBER: 15590420 FILING DATE: 05/09/2017
PATENT NUMBER: 10287528 ISSUE DATE: 05/14/2019
TITLE: OMEGA-3 FATTY ACID ESTER COMPOSITIONS

APPLICATION NUMBER: 15605972 FILING DATE: 05/26/2017
PATENT NUMBER: ISSUE DATE:
TITLE: SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS
AND THEIR USE IN THE TREATMENT OF DISEASE STATES

APPLICATION NUMBER: 29576454 FILING DATE: 09/02/2016
PATENT NUMBER: D790861 ISSUE DATE: 07/04/2017
TITLE: ORAL CARE IMPLEMENT

APPLICATION NUMBER: 61618161 FILING DATE: 03/30/2012
PATENT NUMBER: ISSUE DATE:
TITLE: OMEGA-3 COMPOSITIONS AND METHODS FOR ENHANCING SYSTEMIC
ABSORPTION

APPLICATION NUMBER: 61775865 FILING DATE: 03/11/2013
PATENT NUMBER: ISSUE DATE:
TITLE: PHARMACEUTICAL COMPOSITIONS

APPLICATION NUMBER: 61871415 FILING DATE: 08/29/2013
PATENT NUMBER: ISSUE DATE:
TITLE: FORMULATIONS FOR SOLUBILIZING HORMONES

APPLICATION NUMBER: 61946924 FILING DATE: 03/03/2014
PATENT NUMBER: ISSUE DATE:
TITLE: DRUG DELIVERY SYSTEMS CONTAINING MONOGLYCERIDES

APPLICATION NUMBER: 62026717 FILING DATE: 07/21/2014
PATENT NUMBER: ISSUE DATE:
TITLE: FORMULATIONS FOR SOLUBILIZING HORMONES

APPLICATION NUMBER: 62062634 FILING DATE: 10/10/2014
PATENT NUMBER: ISSUE DATE:
TITLE: OMEGA-3 FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE
TREATMENT OF MACULAR DEGENERATION

APPLICATION NUMBER: 62062638 FILING DATE: 10/10/2014
PATENT NUMBER: ISSUE DATE:
TITLE: OMEGA-3 FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE
TREATMENT OF FAT MALABSORPTION SYNDROMES

APPLICATION NUMBER: 62062643 FILING DATE: 10/10/2014
PATENT NUMBER: ISSUE DATE:
TITLE: OMEGA-3 FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE
TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS

APPLICATION NUMBER: 62062646 FILING DATE: 10/10/2014
PATENT NUMBER: ISSUE DATE:
TITLE: OMEGA-3 FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE
TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC
STEATOHEPATITIS

Application Number:	61871415
Application Number:	61946924
Application Number:	62026717
Application Number:	62062638
Application Number:	62062643
Application Number:	62062646
Application Number:	62062651
Application Number:	62062652
Application Number:	62062634
Application Number:	14578709
Application Number:	14578692
Application Number:	14578697
Application Number:	62207072
PCT Number:	US2015054933
Application Number:	15132278
Application Number:	15134419
Application Number:	15134417
Application Number:	15180430

CORRESPONDENCE DATA

Fax Number: (919)653-0435
Phone: 919.573.7439
Email: USPATENT@NEXSENPRUET.COM

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Correspondent Name: E. ERIC MILLS
Address Line 1: 4141 PARKLAKE AVENUE
Address Line 2: SUITE 200
Address Line 4: RALEIGH, NORTH CAROLINA 27612

ATTORNEY DOCKET NUMBER:	060971-00005
NAME OF SUBMITTER:	E. ERIC MILLS
Signature:	/E. Eric Mills/
Date:	06/20/2019

Total Attachments: 19

source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page1.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page2.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page3.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page4.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page5.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page6.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page7.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page8.tif
 source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page9.tif

source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page10.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page11.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page12.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page13.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page14.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page15.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page16.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page17.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page18.tif
source=Executed_IP_Security_Agreement-Micelle-Pinnacle#page19.tif

RECEIPT INFORMATION

EPAS ID: PAT5582872

Receipt Date: 06/20/2019